

An ISO 9001 & ISO 13485 Certified Company

Date: 12th December, 2023

| То, | То, |
|--|--|
| BSE Limited ("BSE"), | National Stock Exchange of India Limited ("NSE") |
| Corporate Relationship Department, | "Exchange Plaza", 5 th Floor, |
| 2 nd Floor, New Trading Ring, | Plot No. C/1, G Block, |
| P.J. Towers, Dalal Street, | Bandra-Kurla Complex, Bandra (East), |
| Mumbai – 400 001 | Mumbai – 400 051 |
| BSE Scrip code: 543399 | NSE Symbol: TARSONS |

Subject: Outcome of the Board meeting held on Tuesday, 12th December, 2023

Dear Sir/Madam,

The Board of Directors of Tarsons Products Limited ('the Company' or 'Tarsons') at its meeting held today i.e., on Tuesday, 12th December, 2023, which commenced at **04:30 P.M.** and concluded at **07:00 P.M.**, and have inter alia considered and approved the following:

1. Approval of Loan to Wholly Owned Subsidiary

The Board of Directors of the Company in its meeting held today has approved to make investments of up to maximum 13 million euros either by the way of subscription to the shares or through paying the existing loans

Details as required under the Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023, is enclosed as Annexure – A

This intimation will also be hosted on the website of the Company at www.tarsons.com

We request you to take the above information on record.

Thanking You,

Yours Faithfully,
For Tarsons Products Limited

Santosh Kumar Agarwal Company Secretary & Chief Financial Officer ICSI Membership No. 44836

Annexure – A

| SI. No. | Particulars | Details |
|------------|--|---|
| I. | Name(s) of parties with whom the agreement is entered | Tarsons Life Science Pte Ltd |
| II. | Purpose of approval of entering into the agreement | To provide loan for business purposes to the subsidiary |
| III. | Shareholding, if any, in the entity to whom the agreement is executed | 100% wholly owned Subsidiary |
| IV. | Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship. | The Promoters are the Directors in Tarsons Life Science Pte Ltd, the wholly owned subsidiary of the Company |
| V. | Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"; | Yes and it falls under the arm's length basis. |
| VI. | In case of issuance of shares to the parties, details of issue price, class of shares issued; | Not Applicable |
| VII. | any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc; | Not Applicable |
| VIII. | in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): | |
| | a) name of parties to the agreement; | |
| | b) nature of the agreement; | Not Applicable |
| | c) date of execution of the agreement; | |
| | d) details of amendment and impact thereof or reasons of termination and impact thereof. | |